Houston firm scores 2 grants to support testing treatment for addiction, neurodegenerative diseases

money moves

Fannin Partners received two grants to continue developing a new treatment for both addiction medicine and neurodegenerative diseases. Photo via Pexels

A Houston organization devoted to developing early-stage therapeutic and medical device technologies announced fresh funding for one of its startups.

Fannin Partners' Goldenrod Therapeutics, received a $320,000 Phase I SBIR grant from the National Institute on Drug Abuse (NIDA) for studies regarding both addiction medicine and neurodegenerative diseases with a single lead candidate, called 11h.

The grant will fund studies in rodent models of methamphetamine addiction and the efficacy of 11h for the tiny patients. This is the next step in charting the established promise of 11h in substance use disorders using animal models. Existing therapies for opioid and alcohol addiction have high relapse rates, and there are currently no FDA-approved medications for Stimulant Use Disorders (StUDs).

Previous preclinical studies demonstrated that 11h was effective in the fight against cocaine addiction. The goal is to note similar results in methamphetamine addiction.

At the same time, Fannin was also granted a $250,000 Early Hypothesis Development Award from the Department of Defense (DoD) to study 11h in neurodegenerative diseases. Specifically, the funds will be used to work on rodent models of multiple sclerosis (MS).

Fannin’s goal is to develop an oral medication that slows or reverses the progression of MS, while also improving the patient’s quality of life by relieving symptoms. Many MS medications come with the threat of liver injury and increased risk of infection, so sidestepping those is also a hope for 11h.

In fact, 11h was developed to minimize the toxicities associated with existing PDE4 inhibitors. Early evidence shows that the drug is not only effective, but also safe and easily tolerable.

“NIDA’s continued support of our SUD program highlights the potential of 11h to significantly improve the standard of care for patients suffering from these conditions, some of which lack any approved pharmaceutical options," says Dr. Atul Varadhachary, managing partner at Fannin, in a news release. “The additional DoD funding will allow us to explore 11h’s impact on neurodegenerative disease, as well. We are grateful for the support from both organizations as we advance 11h towards clinical development.”

Previous steps in 11h’s development were funded by a $350,000 Phase I SBIR grant from NIDA. 11h is part of NIDA’s Addiction Treatment Discovery Program. Next year, Fannin will likely scale up Good Manufacturing Practices (GMP) production and complete toxicology studies. This will lead to clinical trials for 11h for cocaine use disorder and other StUDs. But don’t expect Fannin to be quiet for long. Its next big discovery is always on the horizon.

From Your Site Articles
Clockwise from top left: Jesse Martinez, Adrianne Stone, Phillip Yates, Carlos Estrada, Atul Varadhachary, and Juliana Garaizar. Photos courtesy

Top innovation leaders talk Houston's strengths, weaknesses

finalists weigh in

The six finalists in this year's Ecosystem Builder category for the Houston Innovation Awards shared many reasons why Houston has been a great place for them to launch their startups.

Still, they've seen first-hand how Houston can grow and change to better support founders like themselves. We asked each to share their thoughts on the strengths and weaknesses of the local innovation ecosystem and about the roles they're playing in the scene's evolution. Scroll down to see what each finalist had to say.

Secure your tickets to the November 14 event.


What are the strengths of the Houston innovation ecosystem?

Adrianne Stone, founder of Bayou City Startups: "Outside of our obvious advantages in health care, energy and space technology I would say that our biggest strength is in the diversity of our community. Everyone brings such unique perspectives, experiences, and ideas to the table that it allows Houston to truly think outside of the box when we leverage that superpower."

Atul Varadhachary, managing partner at Fannin Innovation Studio: "The city benefits from its strategic location as a hub for various industries, including energy, aerospace and health care/biotechnology. This diversity of sectors fosters cross-pollination of ideas and expertise, promoting innovation in multiple fields. In the biotechnology field, the Texas Medical Center in Houston, is a major driver of intellectual capital and contributes to a highly skilled workforce. This potential has not been fully leveraged as yet, but I have seen and contributed to much progress over the last three decades."

Carlos Estrada, growth partner at First Bight Ventures and head of venture acceleration at BioWell: "Houston’s strengths lie in its diverse industries, from energy to health care to bioindustrial manufacturing and its academic institutions which nurture talent and innovation. A new wave of startup organizations also provides startups and SMBs with mentorship, funding opportunities, and critical networking connections. This combination of industry diversity, academic excellence and supportive organizations creates an ideal environment for startups to grow."

Jesse Martinez, founder and CEO of invincible: "The Houston innovation ecosystem continues evolving as it naturally pivots and iterates like a startup. We have a number of existing and new stakeholders who deeply care about Houston, as we all work together to make it a global tech hub destination. Through our SDOs, TMC, Houston Methodist, Helix Park, The Ion, NASA, our universities, and startup community leaders, it's all about us helping to connect the dots for our entrepreneurs so they may grow and thrive in Houston."

Juliana Garaizar, founding partner of Energy Tech Nexus: "Houston has the talent, the corporations and the great intersection of industries were innovations happen: energy, medical and space. Houston knows how to do hard things. We are doers, and we know how to build on our key strengths and are resilient when things don't go according to plan. Our geographic situation and our port make us a global hub and the most diverse city in the U.S."

Phillip Yates, CEO of Equiliberty Inc.: "I believe Houston's innovative ecosystem's greatest strengths reside in its diverse group of citizens and our healthy local economy, which includes the energy sector, medical, and aerospace industries."

What are the weaknesses of the Houston innovation ecosystem? Are you helping to make improvements to these weaker aspects of the community and, if so, how?

Stone: "The first thing that comes to mind is a lack of early stage funding for startups, especially for those with founders from underserved backgrounds. And the second thing is the sheer size of our geographic distribution makes it hard for folks to connect and those kismet collisions to occur. I'm working to improve this by inviting investors to our events, networking more broadly outside of the region and inviting folks to come back to visit, and by hosting a predictable recurring meetup every month so folks can get plugged into the broader ecosystem."

Varadhachary: "In the life sciences space, where I primarily play, our biggest challenge is that the early-stage drug development process is complex and requires direct product development experience. At Fannin, I have helped address this challenge by creating one of the largest talent development programs in the U.S., boasting over 350 alumni. I am especially proud of our alumni diversity — about half are women and most are BIPOC. Fannin draws from local institutions and major institutions across the country. Half of our alumni remain in Houston, many of whom, alongside students I’ve taught, have gone on to join or found startups. Other Fannin alumni have joined major companies around the U.S. and have often come back to help support our local ecosystem."

Estrada: "Houston’s biggest challenge is limited early-stage venture capital. To address this, I organized pitch events at WeWork Labs to attract outside investors and guided startups on how to raise funds while keeping their headquarters in Houston. Furthermore at Rice University’s Liu Idea Lab and Rice Alliance, supporting commercialization was key to launching more local scientist-entrepreneur-led startups. Through First Bight Ventures, I also support local startups like Via Fuels and attract outside startups to scale their manufacturing operations in Houston, further growing the ecosystem."

Martinez: "The current weaknesses of our current Houston innovation ecosystem is two-fold: We need true early stage capital (pre-seed and seed) to support our founders. We also need more incubators and accelerators across the Houston area to support our geographically disbursed founders and founders-to-be in The Woodlands, Katy, and Sugar Land, along with more in central Houston. At invincible, we are committed to helping support and champion our Houston-area innovation community by launching a Mom Tech Incubator (HERA), an early-stage fund, and an industry-specific venture studio. Long term, we will need a growth-stage fund to better support our local startups and those expanding here for strategic reasons."

Garaizar: "Although Houston has a lot of later stage capital, access to early stage capital is a weakness that we are trying to overcome with capital activation, formation and innovation finance. Although Houston is the most diverse city in the U.S. it is not the most inclusive and equitable, that is why I studied the gender gap in investing and launched initiatives like Portfolia or the Houston Equitable Energy Transition Initiative and I am part of the City of Houston's Women Commission."

Yates: "Houston has a problem with economic disparities, including income inequality, poverty, and lack of access to resources. These economic indicators create real barriers for some individuals to have meaningful access to the Houston innovative ecosystem.Through my work with Equiliberty and other non-profits, I have provided my time and resources to help build a more equitable ecosystem. Through the work I am doing with Equiliberty, Houston Area Urban League, Impact Hub and others, I believe we're making improvements to ensure that any person with a dream of changing the world can do it right here in Houston, Texas. We are all working towards the day when their ZIP code, education background or financial status will not be a determining factor."

This week's roundup of Houston innovators includes Navin Varadarajan of the University of Houston, Kelly Pracht of nVenue, and Atul Varadhachary of Fannin. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes two health tech innovators and a sportstech CEO.

Kelly Pracht, CEO and co-founder of nVenue

Kelly Pracht joins the Houston Innovators Podcast to discuss how she's expanded nVenue to new sports. Photo courtesy of nVenue

All though career technologist Kelly Pracht began her entrepreneurial journey with her favorite sport, baseball, she's recently expanded the data-backed, fan-engaging sports betting platform to new sports.

Pract, who spent nearly 20 years designing technologies at Hewlett Packard Enterprise, founded nVenue in 2019 after realizing that, while there's endless data and stats available in baseball, there's nothing that exists for fans to engage in that data in real time. So, she set out to build it herself.

At first, the platform launched as a direct-to-fans platform, but Pracht says on the Houston Innovators Podcast that the company pivoted to B-to-B amid its participation in the Comcast SportsTech accelerator.

"The industry was super hungry for fan engagement and sports betting, and we were one of the only companies that could do it," she says on the show. "We found this huge product-market fit of the whole industry wanting ways to engage and bet in real time." Read more.

Exclusive: 2 Houston health care institutions team up to develop cancer-fighting treatments

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics. Photo via Getty Images

Two Houston organizations announced a new collaboration in a major move for Houston’s biotech scene.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, Varadhachary, explained to InnovationMap in May. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.” Read more.

Earlier this year, Varadhachary joined the Houston Innovators Podcast to discuss Fannin's innovation approach and contribution to medical development in Houston. Listen to the episode below.

Navin Varadarajan, M.D. Anderson Professor of William A. Brookshire Chemical and Biomolecular Engineering at University of Houston

The University of Houston's Navin Varadarajan explains that while COVID vaccines prevent advanced disease, they don’t prevent transmission. But he has a solution. Photo via UH

Since the force of COVID-19 hit globally in 2020, scientists have made efficient progress in the fight against it. As Dr. Navin Varadarajan puts it, vaccines have “allowed us to become a society again.”

And he should know, the M.D. Anderson Professor of William A. Brookshire Chemical and Biomolecular Engineering at University of Houston just published back-to-back studies for nasal sprays that combat viruses. One, the NanoSTING therapeutic, has proven effective in treating strains of SARS-CoV-2 and the flu virus. The other, NanoSTING-NS Pan-coronavirus Vaccine is targeted at preventing the transmission of multiple COVID variants altogether.

Why a nasal vaccine? Varadarajan explains that while COVID vaccines prevent advanced disease, they don’t prevent transmission.

“Intramuscular vaccines do not facilitate a component of peer immunity called mucosal immunity, which takes care of these points of entries, these wet surfaces, which can be of the nose and the wet surfaces of the nose, and so they don't prevent transmission,” he tells InnovationMap. “So I can be vaccinated, I pick up a small infection that's confined largely to my nostrils, and I can still pass it on to vulnerable people, the aged, the immunocompromised people who have all the drugs they're taking to fight other things, like cancer patients. And so for them, the vaccines tend to be less efficacious, and if I transfer it to them, unfortunately they can end up in a hospital, right? And so preventing transmission is the way to end this cycle.” Read more.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics. Photo via Getty Images

Exclusive: 2 Houston health care institutions team up to develop cancer-fighting treatments

collaboration station

Two Houston organizations announced a new collaboration in a major move for Houston’s biotech scene.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, Varadhachary, explained to InnovationMap in May. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.”

The pairing of Fannin and MD Anderson makes perfect sense. Researchers at the institution have already identified novel markers that they will target with both Raptamer-based drugs and radiopharmaceutical/radioligand therapies.

“MD Anderson and Fannin bring highly complementary capabilities to the identification of novel cancer targets and Raptamer-based drug discovery,” says Varadhachary in a press release. “Our collaboration will enable us to rapidly develop targeted therapeutics against novel targets, which we hope will offer hope to patients with progressive cancers.”

Early in this meeting of minds, researchers will focus on developing targeted radiopharmaceuticals — the Radiomers for which Varadhachary’s company is named — as well as targeted drug conjugates that utilize Raptamers. Raptamers are an innovative class of targeting vectors that combine a DNA oligonucleotide backbone with added peptide functionality, for oncology indications.

“We are committed to exceptional research that can help us further our understanding of cancer and develop impactful therapeutic options for patients in need,” says Timothy Heffernan, Ph.D., vice president and head of therapeutics discovery at MD Anderson. “Fannin’s Raptamer drug discovery platform represents an innovative new modality that offers the potential to enhance our portfolio of novel therapies, and we look forward to the opportunities ahead.”

Fannin and MD Anderson will design translational studies together and collaborate to select promising targets for drug discovery. This is a great deal for Fannin, which will retain commercialization rights for the assets that are developed. But MD Anderson won’t be left out; the institution is eligible to receive some payments based on the success of Radiomers and other Raptamer-based drugs developed through the collaboration.

Earlier this year, Varadhachary joined the Houston Innovators Podcast to discuss Fannin's innovation approach and contribution to medical development in Houston. Listen to the episode below.

Radiomer Therapeutics has launched under Fannin Partners with an undisclosed amount of seed funding. Photo via Getty Images

Early-stage cancer-fighting startup raises pre-seed, launches under Houston life science leader

ready to grow

Fannin Partners has done it again. The Houston-based life science development group behind medtech companies Procyrion and Allterum Therapeutics announced yesterday that it has launched Radiomer Therapeutics. With an undisclosed amount of pre-seed funding, Radiomer joins the $242 million-strong Fannin portfolio.

Radiomer uses Fannin’s proprietary Raptamer platform to target vectors and ligands for theranostic application. The cancer-fighting technology is a targeting agent that can address serious maladies including breast, lung, colorectal, prostate, and head and neck cancers.

And with Radiomer’s launch, Fannin is moving with its trademark aggressiveness. Lead programs expected to complete Phase 0 imaging/dosimetry trial(s) in cancer patients in the first quarter of next year. Those will be closely followed by therapeutic programs.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, says in a press release. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.”

Varadhachary has operated Radiomer in stealth mode since its 2023 inception. However, Raptamer has been in the company’s portfolio since 2019. The new company has been using the platform to generate data with the rights to radiopharmaceutical applications for the past year.

“Our lead programs include Radiomers targeting both well-established and first-in-class cancer targets,” adds Dr. Phil Breitfeld, Radiomer’s chief medical officer. “Our imaging/dosimetry trials are designed to provide clinical evidence of tumor targeting and biodistribution information, positioning us to rapidly initiate a therapeutic program(s) if successful.”

For over a decade, Fannin has developed and supported promising life science innovations by garnering grant funding and using its team of expert product developers to build out the technology or treatment. The life science innovation timeline is very different from a software startup's, which can get to an early prototype in less than a year.

"In biotech, to get to that minimally viable product, it can take a decade and tens of millions of dollars," Varadhachary said on the Houston Innovators Podcast earlier this year.

This week's roundup of Houston innovators includes Aziz Gilani of Mercury, Yaxin Wang of the Texas Heart Institute, and Atul Varadhachary of Fannin Innovation. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Welcome to another Monday edition of Innovators to Know. Today I'm introducing you to three Houstonians to read up about — three individuals behind recent innovation and startup news stories in Houston as reported by InnovationMap. Learn more about them and their recent news below by clicking on each article.


Aziz Gilani, managing director at Mercury

Aziz Gilani, managing director at Mercury, joins the Houston Innovators Podcast. Photo via LinkedIn

Aziz Gilani's career in tech dates back to when he'd ride his bike from Clear Lake High School to a local tech organization that was digitizing manuals from mission control. After years working on every side of the equation of software technology, he's in the driver's seat at a local venture capital firm deploying funding into innovative software businesses.

As managing director at Mercury, the firm he's been at since 2008, Gilani looks for promising startups within the software-as-a-service space — everything from cloud computing and data science and beyond.

"Once a year at Mercury, we sit down with our partners and talk about the next investment cycle and the focuses we have for what makes companies stand out," Gilani says on the Houston Innovators Podcast. "The current software investment cycle is very focused on companies that have truly achieved product-market fit and are showing large customer adoption." Read more.


Yaxin Wang, director of the Texas Heart Institute's Innovative Device & Engineering Applications Lab

The project is funded by a four-year, $7.8 million grant. THI will use about $2.94 million of that to fund its part of the research. Photo via texasheart.org

The United States Department of Defense has awarded a grant that will allow the Texas Heart Institute and Rice University to continue to break ground on a novel left ventricular assist device (LVAD) that could be an alternative to current devices that prevent heart transplantation and are a long-term option in end-stage heart failure.

The grant is part of the DOD’s Congressionally Directed Medical Research Programs (CDMRP). It was awarded to Georgia Institute of Technology, one of four collaborators on the project that will be designed and evaluated by the co-investigator Yaxin Wang. Wang is part of O.H. “Bud” Frazier’s team at Texas Heart Institute, where she is director of Innovative Device & Engineering Applications Lab. The other institution working on the new LVAD is North Carolina State University.

The project is funded by a four-year, $7.8 million grant. THI will use about $2.94 million of that to fund its part of the research. As Wang explained to us last year, an LVAD is a minimally invasive device that mechanically pumps a person’s own heart. Frazier claims to have performed more than 900 LVAD implantations, but the devices are far from perfect. Read more.

Atul Varadhachary, managing director of Fannin Innovation

Atul Varadhachary also serves as CEO and president of Allterum Therapeutics. Photo via LinkedIn

Allterum Therapeutics, a Houston biopharmaceutical company, has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

The funds will support the clinical evaluation of a therapeutic antibody that targets acute lymphoblastic leukemia (ALL), one of the most common childhood cancers.

However, CEO and President Atul Varadhachary, who's also the managing director of Fannin Innovation, tells InnovationMap, “Our mission has grown much beyond ALL.” Read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

6 Houston entrepreneurs land on coveted Inc. Female Founders 500 list

the future is female

Six Houston female entrepreneurs and innovators were named to the 2026 Female Founders 500 list.

The annual list compiled by Inc. Magazine recognizes female founders based in the U.S. who have built businesses that have moved their industries forward. The group collectively generated approximately $12.3 billion in 2025 revenue and $12.2 billion in funding to date, according to Inc. Five Houstonians were named to the list last year.

"Each year, we are increasingly amazed by the extraordinary leaders on our Inc. Female Founders 500 list," Bonny Ghosh, editorial director at Inc., said in a news release. "The honorees on this year's list include innovators in AI, beauty and wellness trendsetters winning devoted fans, and nonprofit leaders making a real impact in their communities. Together, they're showing all of us what trailblazing female leadership looks like."

The Houston founders are:

  • Sassie Duggleby, CEO and co-founder of Houston space tech and engine company Venus Aerospace. Duggleby also serves on the Texas Space Commission board of directors.
  • Stephanie Murphy, CEO and executive chairman of Aegis Aerospace, which provides space services, spaceflight product development, and engineering services. Murphy also serves as chair of the Texas Aerospace Research and Space Economy Consortium Executive Committee.
  • Laureen Meroueh, CEO and founder of Hertha Metals, which has developed a cost-effective and energy-efficient process that converts low-grade iron ore of any format directly into molten steel or high-purity iron in a single step.
  • LaToshia Norwood, managing partner of L'Renee & Associates (LRA), a full-service project management consulting firm.
  • Lauren Rottet, president and founding principal of Rottet Studio, an international architecture and design firm focused on corporate, lifestyle and hospitality projects
  • Nina Magon, founder and CEO of Nina Magon Studio / Nina Magon Consumer Products, a residential and commercial interior design company. She also co-founded KA Residences earlier this year.

"Grateful to be recognized again on the Inc. Female Founders 500," Duggleby said in a LinkedIn post. "The best part of building Venus Aerospace has been working with an incredible team pushing the boundaries of flight—and helping bring more women into aerospace along the way.

Meroueh, whose company emerged from stealth last year, voiced a similar push for bringing more women into the fold.

"We've seen a 7x jump in female-led IPOs over the last decade, from just two in 2014 (less than 1% of all IPOs) to 14 in 2024 (nearly 9% of all IPOs). Progress is happening," Meroueh shared in a LinkedIn post. "Yet, less than 1% of venture funding in hard tech goes to female-founded companies. But as my friend Ana Kraft says, the right man for the job may be a woman."

Twenty-nine Texas female founders made this list, including Amber Venz Box, founder of the Dallas-based LTK shopping platform, and Cheryl Sew Hoy, CEO and founder of Austin-based Tiny Health, a fast-growing at-home microbiome health platform. See the full list of winners here.

NASA clears Artemis moon rocket for April launch with 4 astronauts

3, 2, 1...

NASA has cleared its moon rocket on for an April launch with four astronauts after completing the latest round of repairs.

The 322-foot (98-meter) rocket will roll out of the hangar and back to the pad at Florida's Kennedy Space Center, leading to a launch attempt as early as April 1. It will mark humanity's first trip to the moon in more than 50 years.

The Artemis II crew should have blasted off on a lunar flyaround earlier this year, but fuel leaks and other problems with the Space Launch System rocket interfered.

Although NASA managed to plug the hydrogen fuel leaks at the pad in February, a helium-flow issue forced the space agency to return the rocket to the Vehicle Assembly Building for repairs, bumping the mission to April.

The space agency has only six days at the beginning of April to launch before standing down until April 30 into early May.

"It's a test flight and it is not without risk, but our team and our hardware are ready,” NASA's Lori Glaze told reporters at the end of the two-day flight readiness review.

Glaze and other NASA officials declined to provide the risk probabilities for the upcoming mission.

History has shown that a new rocket has essentially a 50% chance of success, said John Honeycutt, chair of the mission management team.

There's so much gap since the only other SLS flight — more than three years ago without anyone on board — that it's difficult to understand any risk assessment numbers, Honeycutt said.

“It's not the first flight," Glaze said. "But we're also not in a regular cadence. So we definitely have significantly more risk than a flight system that's flying all the time.”

Late last month NASA's new administrator, Jared Isaacman, announced a major overhaul of the Artemis program to speed things up and, by doing so, reduce risk.

Dissatisfied with the slow pace and lengthy gaps between lunar missions, he added an extra practice flight in orbit around Earth for next year. That is now the new Artemis III, with the moon landing by two astronauts shifted to Artemis IV. Isaacman is targeting one and maybe even two lunar landings in 2028.

NASA's Office of Inspector General warned in an audit that the space agency needs to come up with a rescue plan for its lunar crews. Landing near the moon's south pole will be riskier than it was for the Apollo astronauts closer to the equator given the rough polar terrain, according to the report.

The report cited the lunar landers as the top contributor for potential loss of crew during the first few Artemis moon landings. It listed the space agency’s loss-of-crew threshold at 1-in-40 for lunar operations and 1-in-30 for Artemis missions overall.

Contracted by NASA to provide the moon landers for astronauts, Elon Musk's SpaceX and Jeff Bezos' Blue Origin have accelerated work in order to meet the new 2028 target date. The inspector general's office said many technical challenges remain including refueling their landers in orbit around Earth before flying to the moon.

NASA sent 24 astronauts to the moon during Apollo, 12 of whom landed on it. All but one of the moonshots — Apollo 13 — achieved their prime objectives. The program ended with Apollo 17 in 1972.

Kinder leads 19 Houstonians on Forbes' World's Billionaires List 2026

World's Richest 2026

According to Forbes, there has “never been a better time to be a billionaire” than in 2026, and the publication's newest World’s Billionaires List has revealed the 19 Houston billionaires that have risen among the wealthiest worldwide.

Kinder Morgan chairman Richard Kinder surpassed hospitality honcho Tilman Fertitta as the richest billionaire in Houston, ranking No. 232 on the global list with an estimated net worth of $13 billion. His net worth has grown by $2.4 billion since last year.

Fertitta, 68, may not be the richest Houstonian anymore, but his wealth is still on the rise. He ranked 268th on the list with an estimated net worth of $11.7 billion, up from $11.3 billion last year.

Out of the 390 billionaire newbies that made their debut onto the list this year, one of them calls Houston home: restaurateur and commodities trader Ignacio Torras. Torras, 61, is the founder and CEO of global commodities trading company Tricon Energy, and he owns Michelin-starred local restaurant BCN Taste & Tradition and its sister eatery MAD. But that's not all he spends his time doing, according to Forbes.

"In 2024 Torras launched a soccer tournament for neurodivergent players called the Genuine Cup," his profile said. "Last year 800 players and 30 teams from around the world played at Rice University stadium."

Torras debuted as No. 2600 on the list with an estimated net worth of $1.5 billion.

Houston-born multi-hyphenate superstar Beyoncé Knowles-Carter also staked a claim among the world's richest people in 2026. She ranked No. 3332 on the list with a net worth of $1 billion, thanks to her "years of music sales, touring and collecting art with her already-billionaire husband Jay-Z (estimated net worth: $2.8 billion)," Forbes said.

"The majority of pop star Beyonce’s net worth comes from her roughly three decades as a solo performer and a member of the girl-group Destiny's Child," her profile said. "She holds the record for the most Grammy wins ever, with 35, and won her first Album of the Year trophy in 2025. She and her billionaire husband Jay-Z purchased a $200 million Malibu mansion in 2023, in what was the most expensive home sale in California history."

Beyoncé also ranks No. 21 in the publication's separate list of The World's Celebrity Billionaires.

Here's how the rest of Houston's billionaires fared on this year's list:

  • Toyota mega-dealer Dan Friedkin: No. 279; $11.4 billion, up from $7.7 billion
  • Pipeline heir Randa Duncan Williams: tied for No. 323 with an estimated net worth of $10.2 billion, up from $9.3 billion in 2025. Fellow pipeline heirs Dannine Avara and Milane Frantz tied for No. 332 globally. Each has an estimated net worth of $10.1 billion, up from $9.2 billion. Scott Duncan ranks No. 353 with a $9.8 billion estimated net worth, up from $9 billion in 2025.
  • Oil tycoon Jeffery Hildebrand: No. 341; $10 billion, up from $7.7 billion
  • Houston Texans owner Janice McNair and family: No. 528; $7.3 billion, up from $6.2 billion
  • Energy exploration chief exec George Bishop of The Woodlands: No. 908; $4.7 billion, down from $5 billion
  • Westlake Corporation co-owners Albert Chao, James Chao and their families: tied for No. 1074; $4 billion, flat from 2025
  • Hedge fund honcho John Arnold: No. 1504; $2.8 billion, down from $2.9 billion
  • Perry Homes executive chair Kathy Britton: No. 1611; $2.6 billion, flat from 2025
  • Houston Astros owner Jim Crane: No. 1676; $2.5 billion, up from $2.4 billion
  • Former Houston Rockets owner Leslie Alexander: No. 1834; $2.3 billion, up from $1.9 billion
  • Mercedes-Benz mega-dealer Joe Agresti: No. 3185; $1.1 billion, flat from 2025
  • Frontier Airlines chairman William Franke: No. 3332; $1 billion, down from $1.2 billion

Elsewhere in Texas

Austin billionaire Elon Musk was declared the world's richest person for the second consecutive year, and Forbes said his “grip on the top spot is as strong as it’s ever been.”

“Musk became the first person to hit $500 billion in wealth, in October,” Forbes said. “Then $600 billion and $700 billion, within four days in December. Then $800 billion, in February.”

The Tesla, SpaceX, and xAI founder’s current net worth has skyrocketed to $839 billion — a shocking $497 billion more than his 2025 net worth.

In Dallas-Fort Worth, Walmart heiress Alice Walton has maintained her elite status as the world’s richest woman for the third year in a row. Walton is the 14th richest person on the planet with a current net worth of $134 billion, an eye-catching $33 billion higher than her 2025 net worth. She is the first American woman worth $100 billion, and one of only 20 “centi-billionaires” worldwide claiming 12-figure fortunes, also known as the "$100 Billion Club."

Koch Inc. stakeholder Elaine Marshall and her family are the richest Dallas residents, ranking No. 71 globally with an estimated net worth of $30.9 billion. Her net worth has grown by $2.6 billion since last year.

---

This article originally appeared on CultureMap.com.

View All Listings